Thiazoloindans and Thiazolobenzopyrans: A Novel Class of Orally Active Central Dopamine (Partial) Agonists
Authors:
- L. Alexander van VlietLVL. Alexander van Vliet
- Nienke RodenhuisNRNienke Rodenhuis
- Håkan WikströmHWHåkan Wikström
- Thomas A. PugsleyTPThomas A. Pugsley
- Kevin A. SerpaKSKevin A. Serpa
- Leonard T. MeltzerLMLeonard T. Meltzer
- Thomas G. HeffnerTHThomas G. Heffner
- Lawrence D. WiseLWLawrence D. Wise
- Mary E. LajinessMLMary E. Lajiness
- Rita M. HuffRHRita M. Huff
- Kjell SvenssonKSKjell Svensson
- Guido R. M. M. HaenenGuido R. M. M. Haenen
- 26 August 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (19) , 3549-3557
Abstract
The 2-aminothiazole moiety has proven its value in medicinal chemistry as a stable and lipophilic bioisosteric replacement of a phenol group. This approach has provided dopamine (DA) agonists with good oral availability. To further explore its use in the development of DA agonists, we have combined the 2-aminothiazole moiety with 2-aminoindans and 3-aminobenzopyrans, which are known templates for DA agonists. In this study we have synthesized 6-amino-3-(N,N-di-n-propylamino)-3,4-dihydro-2H-thiazolo[5,4-f]-[1]benzopyran (12) and 6-amino-2-(N,N-di-n-propylamino)thiazolo[4,5-f]indan (20) and several analogues (13, 17, and 21). The affinity of the thiazolobenzopyrans and thiazoloindans for DA receptors was evaluated, which revealed compound 20 to have high affinity for DA D3 receptors. In addition, the compounds were screened for their potential to inhibit lipid peroxidation, to determine their radical scavenging properties. Compounds 12, 20, and 21 were subjected to further pharmacological evaluation in a functional assay to determine intrinsic activity. Compound 20 was also studied with microdialysis (to determine effects on DA turnover in striatum) and in unilaterally 6-OH-DA lesioned rats (to determine their potential as DA agonists). These studies selected compound 20 (GMC 1111) as particularly interesting. Compound 20 caused a rotation activation in unilaterally 6-OH-DA lesioned rats and an increase in DA turnover in rat striatum. This dual agonist/antagonist action is best accounted for by its partial agonism at striatal DA D2 receptors. Interestingly, 20 displayed long-lasting activity and excellent oral availability in 6-OH-DA lesioned rats, making this compound potentially useful for the treatment of Parkinson's disease.Keywords
This publication has 15 references indexed in Scilit:
- Peripheral markers of oxidative stress in Parkinson’s disease. the role of L-DOPAFree Radical Biology and Medicine, 1999
- Affinity for Dopamine D2, D3, and D4Receptors of 2-Aminotetralins. Relevance of D2Agonist Binding for Determination of Receptor Subtype SelectivityJournal of Medicinal Chemistry, 1996
- Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptorsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine releaseJournal of Neural Transmission, 1994
- The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activityJournal of Neural Transmission, 1993
- Synthesis and cardiotonic activity of novel biimidazolesJournal of Medicinal Chemistry, 1990
- Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analog of apomorphineJournal of Medicinal Chemistry, 1987
- Dopamine receptor agonists: Intrinsic activity vs. state of receptorJournal of Neural Transmission, 1983
- Effects of B‐HT 920 and B‐HT 933 on Dopamine and Noradrenaline Autoreceptors in the Rat BrainActa Pharmacologica et Toxicologica, 1983
- Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine systemBrain Research, 1970